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explants were pre-incubated with the ALK5 inhibitor SB-505124 (50mM)
for 6 hours. Expression of MMP13, ALK5 and ALK1 was analyzed by
quantitative PCR.
Results: Staining for both SMAD2/3P and SMAD1/5/8P was observed in
human OA cartilage. Strikingly, SMAD2/3P staining was mostly negative
in histological intact cartilage areas while cells in damaged areas, mainly
in chondrocyte clusters, were often strongly positive. Also staining for
SMAD1/5/8P was most intense in cells surrounding damaged regions and
chondrocyte clusters. Incubation of human OA cartilage with TGF beta
signiﬁcantly down regulated MMP13 expression. This effect was totally
abolished by the ALK5 inhibitor SB-505124. TGF beta also signiﬁcantly
elevated ALK5 expression, and decreased ALK1 expression, and both
these effects were completely blocked by pre-incubation with SB-
505124.
Conclusion: Stimulation of human end-stage OA cartilage with high TGF
beta concentrations down regulates MMP13 expression and modulates
TGF beta type I receptors, increasing the ALK5/ALK1 ratio. These effects
all run via SMAD2/3 (ALK5). We propose, based on these results and
earlier ﬁndings, that during aging TGF beta loses its protective role
by a loss of SMAD2/3 signaling in articular chondrocytes. This loss
plays a role in the initiation of cartilage degradation. In end-stage
OA cartilage the majority of cells does not display either SMAD2/3P
or SMAD1/5/8P. However, neighboring severely damaged cartilage a
population of chondrocytes is present, most probably involved in
(unsuccessful) repair, that expresses SMAD2/3P and SMAD1/5/8P.
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MOLECULAR DETECTION OF A PRECURSOR STAGE OF OSTEOARTHRITIS
IN RNA FROM CARTILAGE OF YOUNG ADULTS WITH HIP PAIN
S. Hashimoto, L.J. Sandell, J.C. Clohisy. Washington Univ. Sch. of Med., St.
Louis, MO, USA
Purpose: Developmental dysplasia of hip (DDH) is recognized as a
potential risk factor for hip pain in young adults and a risk factor
for development of hip osteoarthritis (OA). Recently, femoroacetabular
impingement (FAI), with other dysmorphic and orientation abnormalities
of the hip joint, has been reported. Both conditions were presumed to be
in an early stage of degeneration based on their long term history and
radiographic evaluations, however, there are no reports of a biological
basis for early OA or discrimination of DDH and FAI. Therefore, the
purpose of this study was to determine the metabolic proﬁle of the
cartilage at the time of hip surgery to reshape the hip.
Methods: Fifty nine cartilage samples were obtained from patients
who had FAI (n = 26), DDH (n=13), and structural instability with
impingement (combined) (n = 20), at the time of their joint preservation
surgery, either surgical dislocation or/and periacetabular osteotomy.
Cartilage samples from 2 children were used as normal control, and
7 OA samples were used as disease controls. All cartilage samples were
harvested from their femoral neck junctions, and RNAs were extracted.
These cartilage samples were evaluated by real-time PCR assay of
gene expression of cytokines and chemokines, matrix molecules, and
degradative enzymes. The macroscopic cartilage damage was classiﬁed
by Beck’s criteria (normal, malacia, cleavage, and defect).
Results: RNA from both diseases presented high levels of speciﬁc
inﬂammatory cytokines (IL-1b and IL-8), chemokines (CXCL2, CXCL3,
CXCL6, CCL3 and CCL3L1), and degenerative mediators (MMP-13 and
ADAMTS-4), and this expression was higher in FAI than DDH or
combined. In addition, expression of Type II collagen (Col2A1) and
Aggrecan were higher in FAI compared to DDH and combined samples
(Figure 1).
Stratiﬁcation by age (<20 y.o., ≥20 y.o.) showed that older DDH and
combined samples expressed higher levels of some chemokines (CCL3L1
in DDH, CXCL1 and CXCL2 in combined) and catabolic enzymes (MMP-
13 in DDH, ADAMTS-4 in combined). In addition, the Col2A1 level was
lower in older samples (Figure 2).
Comparison between Beck’s classiﬁcation showed a higher expression of
a speciﬁc cytokine (IL-8), chemokines (CXCL1, CXCL3, CXCL6, and CCL3L1),
and ADAMTS-4 in samples with cartilage cleavage. Col2A1 expression
was gradually increased with advancing cartilage damage, while less
expression in OA samples.
Conclusions: The cartilage condition in both diseases is considered pre-
OA, based on the lack of radiographic OA. The cartilage of FAI has a high
level of metabolic activity with more arthritic character (high catabolic
factors) but also a regenerative response (high Col2A1 and Aggrecan).
In both DDH and combined patients, the overall level of metabolic
activity was lower than FAI, however the expression of degenerative
enzymes was age-dependent indicating cartilage degradation especially
in older patients. Therefore, both age and OA-related symptoms need
to be taken into account when considering surgical intervention. We
hypothesize that joint preservation surgery would decrease stress on
the articular cartilage and lower metabolic activity. In conclusion, we
have demonstrated that hip cartilage from young patients with FAI and
DDH has a unique biological character, which may lead to identiﬁcation
of speciﬁc biomarkers for detection of early degenerative changes and
outcomes following treatment.
Fig. 1. Expression levels of cytokines, matrix molecules, and chemokines
in FAI, DDH and combined samples. RNA expression was normalized
to GAPDH mRNA and then compared with normal cartilage samples
(set at 1). *Signiﬁcant difference between normal control.
Fig. 2. Stratiﬁcation by age (<20 y.o., ≥20 y.o.) in each disease. RNA
expression was normalized to GAPDH mRNA and then compared with
normal cartilage samples (set at 1). *Signiﬁcant difference between each
age group.
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EVALUATION OF THE EFFICACY OF IL-1R ANTAGONISTS IN HUMAN
CARTILAGE DEGRADATION EX VIVO
J.T. Hulme1, K. Merriam2, J.B. Rottman2, G.D. Virca1, J.E. Sims1,
C.A. Gabel1. 1AMGEN, Seattle, WA, USA; 2AMGEN, Cambridge, MA, USA
Purpose: Osteoarthritis is the most common chronic joint disorder in
the US, affecting nearly one-tenth of the population. It is characterized
by degeneration of the articular cartilage, limited intra-articular
inﬂammation and synovitis, changes in sub-chondral bone and pain.
Nothing in the current standard of care preserves cartilage or carries a
claim of disease modiﬁcation in osteoarthritis; standard treatments focus
on symptom relief using NSAIDs, injected steroids, and viscosupplements.
IL-1, produced by chondrocytes in OA cartilage, promotes increased
expression and activation of aggrecanases and matrix metalloproteinases
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(MMPs) which degrade the cartilage matrix. Of the cytokines implicated
in the pathophysiology of OA, IL-1 has attracted the most interest as a
target for disease modiﬁcation and IL-1 inhibition has been reported to
be beneﬁcial in several animal models of OA. In considering potential
barriers that may limit the use of biological therapeutics in treating
cartilage-associated diseases, we asked whether two IL-1 receptor
antagonists were capable of penetrating cartilage and reaching the IL-1
receptor on chondrocytes. In the present study we evaluate the efﬁcacy
of IL-1ra (Kineret; ~17 kDa) and a monoclonal IL-1R antibody (6F3;
~150 kDa)) as antagonists of IL-1 in human chondrocytes and cartilage
explants from non-arthritic donors.
Methods: Human primary chondrocytes and cartilage explants (3-
mm diameter) were obtained from Articular Engineering (Chicago, IL).
Chondrocytes and cartilage explants were incubated with Kineret or
6F3 for 30 min prior to stimulation with 1ng/ml IL-1b. MMP-13 levels
in the conditioned media were measured using an MMP-13 Fluorokine
Assay (R&D Systems). Detection of endogenous antibodies in the joints
of rat, wild-type mice or mice expressing human immunoglobulins was
assessed by immunohistochemistry using secondary anti-rat, anti-mouse
or anti-human antibodies.
Results: In human primary chondrocyte cultures, both Kineret and 6F3
were potent inhibitors of IL-1 induced MMP-13 production. Whereas
Kineret retained its potency in cartilage explants, the potency of 6F3 was
dramatically diminished in cartilage explants, suggesting that the larger
molecule was impaired from reaching its target by the extracellular
matrix. To further address whether antibodies penetrate cartilage, the
detection of endogenous antibodies in the joints of rat, wild-type
mice or mice expressing human immunoglobulins was assessed by
immunohistochemistry using secondary anti-rat, anti-mouse or anti-
human antibodies. Endogenous rat, mouse or human antibodies were
not present in either articular or growth plate cartilage. In contrast,
saturating levels of endogenous antibody was detected in the adjacent
ﬁbrocartilage and soft tissues including the synovium, ligaments, the
joint capsule and stroma surrounding bone marrow blood vessels.
Conclusions: Collectively, these data demonstrate that antibodies do
not normally penetrate either articular or growth plate cartilage. As
such, antibodies do not represent a viable therapeutic modality for
targeting chondrocyte-mediated processes. Smaller alternatives such as
Fab′ fragments and non-antibody scaffolds may offer advantages over
antibodies for achieving cartilage penetration.
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TROPHIC EFFECTS OF MESENCHYMAL STEM CELLS INCREASE
CHONDROCYTE PROLIFERATION AND MATRIX FORMATION
L. Wu, J. Leijten, N. Georgi, C.A. van Blitterswijk, M. Karperien. Univ. of
Twente, Enschede, Netherlands
Purpose: Previous studies have shown that co-culture of primary
chondrocytes with various sources of multipotent cells results in a higher
relative amount of cartilage matrix formation than cultures containing
only chondrocytes. The aim of this study is to investigate the mechanism
underlying this observation.
Methods: Cell culture: Human primary chondrocytes (PC) were isolated
from cartilage biopsies of patients undergoing total knee replacement
after collagenase II digestion. Human mesenchymal stem cells were
isolated from bone marrow aspirates. The use of all human biopsies
in this study was approved by a local Medical Ethical Committee.
Histology: Cell pellets were ﬁxed and embedded in parafﬁn
using routine procedures. Sections were cut and stained for
sulfated glycosaminoglycans (GAG) with alcian blue combined with
counterstaining of nuclear fast red.
GAG and DNA assay: Cell pellets were were digested with proteinase K to
release GAGs. Then GAG content was spectrophotometrically determined
with 1,9-dimethylmethylene blue chloride using an ELISA reader. Cell
number was determined by quantiﬁcation of total DNA using a CyQuant
DNA Kit.
EdU staining and quantiﬁcation: EdU (5-ethynyl-2′-deoxyuridine) was
added to the culture media to label proliferating cells. Pellets were
cryosectioned and stained for EdU with Click-iT® EdU Imaging Kit.
Nuclei were counterstained with Hoechst 33342. Images were taken
and analyzed with ImageJ.
Short Tandem Repeats (STR) analysis. STR analyses of genomic DNA
samples were performed with PowerPlex 16 System. The amount of
DNA present for each donor was calculated from the areas of the
electropherogram for each locus of MSCs’ or PCs’ speciﬁc alleles and
the ratio of MSCs and PCs was determined.
Results: Cocultures increase GAG formation. Histology and GAG
quantiﬁcation were performed to evaluate cartilage formation. Alcian
blue staining indicated the presence of GAG in all experimental
groups. In the positively stained areas, cells showed typical chondrocyte
morphology and embedding in lacunae. GAG quantiﬁcation showed a
trend of increasing total GAG with increasing initial percentage of PC.
When total GAG content was normalized to the initial percentage of
PC, co-culture pellets showed signiﬁcantly higher GAG content than
monocultures.
Cocultures increase chondrocytes proliferation. Cell proliferation was
then examined by using EdU incorporation. PCs were labeled with CM-
DiI to distinguish them from MSCs. At day 2, EdU positive cells were
predominantly found at the periphery of the pellets where red labeled
PCs resided. The percentage of EdU positive MSCs or PC was determined.
PCs in cocultures proliferate at higher rate than PC in monocutlure.
Ratio of MSCs decreases after coculture. To determine the ratio of MSC
and PC after coculture STR loci in different donors were analyzed. The
results indicated that the proportion of MSCs decreased signiﬁcantly
after 4 weeks cocultures.
Conclusions: In pellet cocultures, MSC act as trophic mediators
stimulating cartilage matrix formation by promoting proliferation of
primary chondrocytes rather than differentiating into chondrocytes.
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THROMBIN AND PLASMIN ARE ABLE TO INDUCE PROTEOGLYCAN
RELEASE IN A PAR-INDEPENDENT MANNER IN HUMAN CARTILAGE
L. Nieuwenhuizen1,2, R.E. Schutgens2, G. Roosendaal2, D.H. Biesma2,
S. Mastbergen1, F.P. Lafeber1. 1Rheumatology & Clinical Immunology, Univ.
Med. Ctr. Utrecht, Utrecht, Netherlands; 2Hematology and Van Creveld
Clinic, Univ. Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: Osteoarthritis (OA) and Rheumatoid Arthrisis (RA) are
characterized by degradation of the cartilage. Proteases of the coagulation
cascade and the ﬁbrinolytic system are elevated in both plasma and
synovial ﬂuid of OA and RA patients. Cross-talking between coagulation
and inﬂammation is mediated by protease-activated-receptors (PARs),
a cell membrane receptor family. These receptors are transmembrane
G protein-coupled receptors that are activated through cleavage by
serine proteases, such as thrombin and plasmin. PARs are expressed at
increased levels in human OA and RA synovium and cartilage. Activation
of these PARs results in the induction of catabolic and proinﬂammatory
pathways. Our aim was to study whether thrombin, plasmin and PAR
agonists induce cartilage damage in human healthy and OA cartilage.
Furthermore, we wanted to investigate if thrombin and plasmin induce
cartilage damage in a PAR-dependent manner.
Methods: Healthy full-thickness human articular cartilage tissue was
obtained postmortem within 24 hours after death of the donor. Full-
thickness OA human articular cartilage tissue was obtained during
total knee surgery. Slices of cartilage were cut aseptically from the
articular surface and kept in phosphate-buffered saline. Within 1 hour
of dissection the slices were cut into square pieces, weighed aseptically
(range, 5.0 to 15.0mg) and each sample was individually put into culture.
Cartilage was pre-cultured for two days in medium supplemented
with serum. Subsequently, the cartilage was cultured in serum-free
medium. After 24h the serum-free medium was refreshed and cartilage
was cultured for 4 days in serum-free medium in the presence of
different concentrations thrombin (10, 30 or 100nM), plasmin (1, 3, 10,
30 or 100nM), PAR1 agonist TFLLR-NH2(100mM), PAR2 agonist SLIGKV
(100mM), with or without co-culture with PAR1 antagonist SCH79797
(100mM) or PAR2 antagonist FSLLRY-NH2 (100mM). Cartilage matrix
turnover, in terms of proteoglycan synthesis, -release, and -content, was
determined at day 4.
Results: Thrombin and plasmin increased proteoglycan release in both
healthy cartilage and osteoarthritis cartilage in a dose-dependent manner
(471% for thrombin at 100nM; 744% for plasmin at 100nM; both
p < 0.05). Proteoglycan synthesis and content were not signiﬁcantly
changed by thrombin or plasmin. Thrombin-induced and plasmin-
induced proteoglycan release were not affected by co-culture with either
PAR1 antagonist SCH79797, or PAR2 antagonist FSLLRY-NH2. Also the
direct stimulation with PAR1 agonist TFLLR-NH2, or PAR2 agonist SLIGKV
failed to induce proteoglycan release.
